Lung Cancer | Clinical

Many Oncologists Favor Consolidation Immunotherapy Following Chemoradiation for Stage III NSCLC

November 21, 2020

During a Targeted Oncology Case Based Peer Perspectives event, John Heymach, MD, PhD, professor and Chair, David Bruton Jr Chair in Cancer Research. Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discussed the guidelines and therapeutic option for stage III non–small cell lung cancer, based on a case of a 66-year-old patient.

‘State of Lung Cancer’ Report Reveals Worse Outcomes in Patients of Color

November 18, 2020

Patients of color who were diagnosed with lung cancer were associated with worse outcomes compared with Caucasian patients, according to findings from the 3rd Annual “State of Lung Cancer” Report by the American Lung Association.

Tislelizumab Meets Overall Survival End Point in Phase 3 Study of Advanced NSCLC

November 17, 2020

The primary end point of overall survival with tislelizumab compared with docetaxel as the second- or third-line treatment of patients with locally advanced or metastatic non–small cell lung cancer who progressed on previous platinum-based chemotherapy.

A Long-Term Survival Picture Emerges as Follow-up Data From NSCLC Trials Mature

November 16, 2020

Dramatic improvements in efficacy outcomes for patients with non–small cell lung cancer have been a reason for celebration over the last decade, as FDA approvals of immunotherapy-plus-chemotherapy combinations as well as oncogenic-targeting drugs have transformed the treatment landscape.

Inhibitors of MET, RET, and TRK Now Enjoy Standard of Care Status in Lung Cancer

November 09, 2020

Alexander Drilon, MD, chief of Early Drug Development Service at Memorial Sloan Kettering Cancer Center in New York, discussed each of the recently approved agents used for the treatment of these tumors and presented a review of the data at the 15th Annual New York Lung Cancer Symposium.

KRAS Now a Druggable Target in Non–Small Cell Lung Cancer

November 09, 2020

As the field of lung cancers continues to lean further into the precision medicine era, KRAS G12C has become an emerging actionable target for which multiple therapies are under development, said Bob T. Li, MD.